|
|
|
|
| LEADER |
02208nam a2200325 u 4500 |
| 001 |
EB000943761 |
| 003 |
EBX01000000000000000737351 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150223 r ||| eng |
| 100 |
1 |
|
|a Matchar, David B.
|
| 245 |
0 |
0 |
|a Comparative effectiveness of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs) for treating essential hypertension
|h Elektronische Ressource
|c prepared by Duke Evidence-based Practice Center; investigators, David B. Matchar [and eight others]
|
| 260 |
|
|
|a Rockville, MD
|b Agency for Healthcare Research and Quality, Department of Health and Human Services, USA
|c 2007, 2007
|
| 300 |
|
|
|a 1 PDF file (various pagings)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Angiotensin Receptor Antagonists / therapeutic use
|
| 653 |
|
|
|a Hypertension / drug therapy
|
| 653 |
|
|
|a Angiotensin-Converting Enzyme Inhibitors / adverse effects
|
| 653 |
|
|
|a Angiotensin-Converting Enzyme Inhibitors / therapeutic use
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Angiotensin Receptor Antagonists / adverse effects
|
| 710 |
2 |
|
|a Duke University Evidence-based Practice Center
|
| 710 |
2 |
|
|a United States
|b Agency for Healthcare Research and Quality
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Comparative effectiveness review
|
| 500 |
|
|
|a Title from PDF t.p
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK43073
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a In this comparative effectiveness review, we examine the scientific literature on angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs, or angiotensin receptor blockers) for individuals with hypertension regarding their relative benefits (blood pressure control, cardiovascular risk reduction, cardiovascular events, quality of life, and other outcomes), as well as relative risks (safety, adverse events, tolerability, persistence, and adherence). In addition, we will examine the clinical determinants of these outcomes with a focus on the long-term impact
|